Highlighting the importance of this immune shift in disease progression is that restoring cytokines seen in early MF by treating advanced CTCL with IFN-α and IFN-γ is an effective strategy for treatment [66]. The gene discussed is IFNG; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.